Neuronetics reports record Q4 2022 revenue $18.2M (+21% YoY); full year $65.2M

Neuronetics, Inc.

Q4 revenue $18.2M, up 21% YoY; US treatment session revenue record $12.5M.
Full year net loss ($37.2M) or ($1.38) per share vs ($31.2M) or ($1.22) in 2021.
Cash $70.3M at year-end; guides Q1 2023 revenue $15-16M, FY2023 $66-72M.
Expanded Greenbrook partnership through 2028; NGS policy allows NPs to order TMS.
Peer-reviewed publication shows NeuroStar TMS effective for anxious depression.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Neuronetics, Inc. reported the three months ended December 31, 2022 and the year ended December 31, 2022 results: revenue $65.2 million.

Period: the three months ended December 31, 2022 and the year ended December 31, 2022
Revenue: $65.2 million
Result: reported results

Exact text from the filing

of $12.5 million in the fourth quarter 2022 ● Increased NeuroStar System revenue 64% over the fourth quarter of 2021 Full Year 2022 Highlights ● Full year 2022 revenue of $65.2 million, representing an 18% increase as compared to full year 2021 ● Full year 2022 U.S. treatment session revenue of $45.1 million ● Full year 2022 U.S. NeuroStar Advanced Therapy

View on SEC.gov

Browse all earnings releases →

Neuronetics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-002996

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.